Streetwise Reports' Article Archives — July 2024 back to current month (11)
Exercised Warrants Show Confidence in AI-Driven Healthcare Innovations (07/29/2024)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence.
Analyst Says CA Pharma Underappreciated by Investors (07/23/2024)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors.
Analyst's Target Price for Biotech Massively Higher Than Current Price (07/22/2024)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price.
Study Shows 93% Cough Suppression With Co.'s Drug (07/18/2024)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."
Could This Stock Be the Next Bellus Cough Treatment? (07/17/2024)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.
LA Biotech Unveils New Patented Nicotinamide Riboside Chloride (07/15/2024)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report.
Healthcare AI Company Achieves Key Milestones and Secures New Partnerships (07/11/2024)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.
Biopharma Co. Reports Strong FQ224 Results Driven (07/11/2024)
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).
Texas Biotech Announces Plans for Preclinical Obesity Studies (07/08/2024)
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note.
AI Health Stock Heading Higher Expert Says (07/02/2024)
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.
New Patents and Strategic Partnerships Boost Smart Home Innovation (07/01/2024)
SKYX Platforms Corp. (SKYX:NASDAQ), a leader in smart platform technology, has announced the issuance of six additional patents in the U.S. and internationally, expanding its already robust patent portfolio to over 94 issued and pending patents globally. Find out how these partnerships affect upcoming projects and plans.
More Archives
2024Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
